| |
|
|
|
Keystone Symposia, Vancouver, British Columbia, Canada
March 20 - 25, 2007
Tuberculosis remains one of the major infectious disease killers in the world. This is in spite of the fact that, in most cases, the host response is capable of controlling Mycobacterium tuberculosis infection efficiently: only a minority of infected individuals develops active tuberculosis. The situation is exacerbated by increasing incidences of multi-drug-resistant strains and the dangerous liaison between tuberculosis and AIDS. Recent accomplishments in molecular genetics, cell biology, structural biology and immunology have provided the clues to an in-depth understanding of the crosstalk between pathogen and host which leads to latency, resuscitation, disease outbreak, susceptibility and protective immunity. Application of state-of-the-art technologies will help in elucidating underlying molecular mechanisms and in identifying the responsible gene products both on the side of the invader and its host. Based on such insights, novel vaccination strategies can be pursued and new drug candidates developed. This meeting will discuss the most recent findings in the broad field of research activities relevant to a better understanding of tuberculosis and provide a forum for intensive discussions and collaborations for scientists ranging from basic research to field studies. The meeting, therefore, will also promote exchange between and amalgamation of highly sophisticated research approaches and fundamental issues of disease control.
|
|
|
|
|
|
|
|
Organized by:
|
|
Stefan H.E. Kaufmann, Issar Smith and Carl F. Nathan |
|
|
Invited Speakers:
|
|
- Laurent Abel, Faculté de Médecine Necker
- Peter Andersen, Statens Serum Institut
- Tanjore Balganesh, AstraZeneca R and D Bangalore, India
- Helena Boshoff, NIAID, National Institutes of Health
- Mamadou Daffe, Centre National de la Recherche Scientifique
- Thomas Dick, Novartis Institute for Tropical Diseases
- Chris Dye, World Health Organization
- Sabine Ehrt, Weill Medical College of Cornell University
- Pedro Flores-Villanueva, University of Texas Health Center at Tyler
- Uli Fruth, World Health Organization
- Ann Ginsberg, Global Alliance for TB Drug Development
- Rajesh Gokhale, National Institute of Immunology
- Anne Goldfeld, Harvard Medical School
- Jacques Grosset, Johns Hopkins School of Medicine
- Marcus Horwitz, University of California, Los Angeles
- Greg Hussey, University of Cape Town
- William Jacobs, Albert Einstein College of Medicine
- Gilla Kaplan, Public Health Research Institute
- Stefan Kaufmann, Max Planck Institute for Infection Biology-Berlin
- Igor Kramnik, Harvard School of Public Health
- Paul-Henri Lambert, University of Geneva
- Albrecht Läufer, Vakzine Projekt Management GmbH
- Michael Levin, Imperial College School of Medicine
- John MacMicking, Yale University
- John McKinney, Rockefeller University
- Helen McShane, University of Oxford
- Carl Nathan, Cornell University
- Thomas Ottenhoff, Leiden University Medical Center
- Eric Rubin, Harvard School of Public Health
- Jerald Sadoff, Aeras Global TB Vaccine Foundation
- Larry Schlesinger, Ohio State University
- Neil Schluger, Columbia University College of Physicians and Surgeons
- F. Sher, NIAID, National Institutes of Health
- David Sherman, University of Washington
- Christine Sizemore, National Institutes of Health
- Peter Small, Bill & Melinda Gates Foundation
- Issar Smith, Public Health Research Institute
- Alexander von Gabain, Intercell
- Matthias Wilmanns, European Molecular Biology Laboratory
- Douglas Young, Imperial College London
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
Nov. 20, 2006
|
|
|
|
|
|
|
|
Registration:
|
|
Please see website
|
|
|
E-mail:
|
|
info@keystonesymposia.org
|
|
|
|
|
|
|
|
|